TGA expands indication for lanreotide

A medical oncologist has welcomed the TGA’s approval of lanreotide for the control of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

The drug, marketed as somatuline autogel, had previously been approved only for symptom control, and the new indication provides an alternative to radiopeptide therapy, says Dr Tim Price, consultant oncologist at Queen Elizabeth Hospital in Adelaide.